AstraZeneca (AZN) CEO Pascal Soriot is not overly concerned about the threat of tariffs by the Trump administration on pharmaceuticals and said a more favorable corporate tax credit could motivate ...

London: British pharmaceutical giant AstraZeneca announced Tuesday that it has begun moving some of its European production to the United States, ahead of President Donald Trump's possible tariffs ...

CAMBRIDGE, Britain — CAMBRIDGE, Britain — Astrazeneca PLC (AZN) on Tuesday reported first-quarter profit of $2.92 billion. On a per-share basis, the Cambridge, Britain-based company said it ...

April 16 (Reuters) - AstraZeneca's (AZN.L), opens new tab Alexion Pharmaceuticals was sued in Massachusetts federal court on Wednesday in a class action complaint alleging it misused its patents ...

EPS: US$1.88 (up from US$1.41 in 1Q 2024). We've discovered 2 warning signs about AstraZeneca. View them for free. Revenue missed analyst estimates by 1.1%. Earnings per share (EPS) exceeded ...

AstraZeneca AZN1.38%increase; green up pointing triangle posted increased core earnings per share and sales for the first quarter but warned of mounting legal challenges in China. The British ...

AstraZeneca has taken a key step in advancing Breztri Aerosphere toward a potential label expansion and achieving its goal of annual sales of $3 billion to $5 billion for the 3-in-1 inhaler.

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "Our strong growth momentum has continued into 2025 and we have now entered an unprecedented catalyst-rich period for our company.